Opin vísindi

Does autoimmune thyroid disease affects rheumatoid arthritis disease activity or response to methotrexate?

Does autoimmune thyroid disease affects rheumatoid arthritis disease activity or response to methotrexate?

Title: Does autoimmune thyroid disease affects rheumatoid arthritis disease activity or response to methotrexate?
Author: Waldenlind, Kristin
Delcoigne, Bénédicte
Saevarsdottir, Saedis   orcid.org/0000-0001-9392-6184
Askling, Johan
Date: 2020-07-15
Language: English
Scope: e001282
University/Institute: Háskóli Íslands
University of Iceland
School: Heilbrigðisvísindasvið (HÍ)
School of Health Sciences (UI)
Department: Læknadeild (HÍ)
Faculty of Medicine (UI)
Series: RMD Open;6(2)
ISSN: 2056-5933
DOI: 10.1136/rmdopen-2020-001282
Subject: Rheumatoid arthritis; Autoimmune Diseases; Epidemiology; Methotrexate; Patient Reported Outcome Measures; Iktsýki; Sjálfsofnæmissjúkdómar
URI: https://hdl.handle.net/20.500.11815/2295

Show full item record


Waldenlind K, Delcoigne B, Saevarsdottir S, et alDoes autoimmune thyroid disease affect rheumatoid arthritis disease activity or response to methotrexate?RMD Open 2020;6:e001282. doi: 10.1136/rmdopen-2020-001282


Objective: To investigate if autoimmune thyroid disease (AITD) impacts rheumatoid arthritis (RA) disease activity or response to methotrexate. Methods A nationwide register-based cohort study of 9 004 patients with new-onset RA from the Swedish Rheumatology Quality Register year 2006-2016, with linkage to other nationwide registers to identify comorbidity with AITD defined as thyroxine prescription before RA diagnosis, excluding non-autoimmune causes. We compared RA disease activity using 28-joint Disease Activity Score (DAS28) and its components, and EULAR response, between patients with and without AITD, using logistic regression. Results At diagnosis, patient reported outcome measures (PROMs; patient global, Health Assessment Questionnaire Disability Index and pain) but not objective disease activity measures (erythrocyte sedimentation rate and swollen joint count) were significantly higher (p<0.05 for all PROMs) among RA patients with AITD compared with those without. The level of DAS28 was 5.2 vs 5.1. By contrast, AITD had little influence on EULAR response to methotrexate at 3 months (OR of non/moderate response=0.95, 95% CI 0.8 to 1.1), nor at 6 months. When stratified by age, however, AITD was more common among EULAR non/moderate responders at 3 and 6 months in patients below 45 years resulting in ORs of non/moderate response of 1.44 (0.76-2.76) and 2.75 (1.04-7.28). Conclusion At diagnosis, RA patients with concomitant AITD score worse on patient reported but not on objective RA disease activity measures, while DAS28 was only marginally elevated. The overall chance of achieving a EULAR good response at 3 or 6 months remains unaffected, although among a limited subgroup of younger patients, AITD may be a predictor for an inferior primary response. © Author(s) (or their employer(s))


Publisher's version (útgefin grein)


This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

Files in this item

This item appears in the following Collection(s)